SLQT
NYSE SelectQuote Inc$0.3242 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.3242, $0.0216 below the day’s high of $0.3458
- YTD change
- -77.01%
- vs 20-day SMA
- -19.05%
- vs 200-day SMA
- -61.48%
Price ranges
Price & Performance
-0.45 (-58.32%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.0% away from all-time highs of $33.0000
- SLQT is down 77% since the beginning of the year
- SLQT is down 83% over the past 12 months
- SLQT is down 31% over the past 1 month
- 1% of all SLQT investors are betting against SLQT
- Number of investors short SLQT has gone down 19% versus last month
SLQT reads poor: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is -82.4%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0047
- Last 5 days
- -12.52%
- vs 8-day SMA
- -8.99%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
SelectQuote, Inc. is a technology-enabled, direct-to-consumer distribution and engagement platform, which engages in the sale of insurance policies and provision of healthcare services. It operates through the following segments: Senior, Healthcare Services, and Life. The Senior segment primarily sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other senior health insurance products. The Healthcare Services segment provides pharmacy, chronic care management, and other healthcare products and services through SelectRx, Healthcare Select, and SelectPatient Management. The Life segment primarily sells term life and final expense products. The company was founded on August 18, 1999 and is headquartered in Overland Park, KS.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.